The ultimate goal is to prevent defects from recurring so there are no defects to correct.
Even in the case of products for which we have the most stringent of safety rules, such as prescription medicines and motor vehicles, we hear recurring reports of manufacturing defects and of product recalls.
These symptoms of altitudinal field defects recurred with subsequent cycles of reinfusion ultimately resulting in sufficient ischaemia to produce infarction in the form of a non-arteritic anterior ischaemic optic neuropathy (NAION).
No neurological complications were evident upon discharge and the patient had no recurring symptoms or significant residual defects when followed up 2 months later.
In group 2, the defect recurred after the suspension of therapy in 2 (18%) patients; in group 1, no defects recurred.
Indeed germ cell death by defect is a recurring phenomenon observed in a variety of bilaterian species [2].
In 2 patients in group 2, the epithelial defect recurred after the suspension of therapy.
These defects are exacerbated by the recurring problem of investment banks who are conflicted in their provision of fairness opinions.
Of the mutations affecting zebrafish development, only about one-third leads to relatively specific developmental defects while the majority lead to more general and recurring phenotypes manifested by increased neuronal necrosis/apoptosis and developmental delay.
Indeed, patients with defects in caspase-8 are immunodeficient and suffer from recurring infections, and caspase-6 has an essential role in B-cell proliferation.
